Last reviewed · How we verify
Xapit (PARECOXIB)
Parecoxib (Xapit) is a marketed selective COX-2 inhibitor primarily indicated for acute postoperative pain management. Its key strength lies in its mechanism of action, which selectively targets the enzyme responsible for pain and inflammation, potentially offering a safer profile compared to non-selective NSAIDs. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PARECOXIB |
|---|---|
| Drug class | parecoxib |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
- Acute postoperative pain
Common side effects
Key clinical trials
- A Study on Reducing Opioid Use After Minimally Invasive Ankle Surgery (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Study Comparing Dynastat and Parestat Pain Relief Medications for Patients After Breast Surgery (PHASE4)
- TAP Block With Lidocaine and Ropivacaine 0.2% (0.4 ml/kg/Side) for Pain and Opioid Reduction After Hysterectomy (NA)
- Comparative Efficacy of IV Parecoxib vs Lidocaine in Reducing Propofol Injection Pain (NA)
- Parecoxib in Total Knee Arthroplasty (PHASE4)
- Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |